spent around DKK 2.5 billion<\/a> on research centres at the University of Copenhagen since 2007.
\n<\/p>\n","protected":false},"excerpt":{"rendered":"It is the latest huge grant from the Novo Nordisk Foundation to UCPH. Researchers are to find new treatments for two types of blood cancer. The development of drugs for these diseases came to a standstill many years ago.<\/p>\n","protected":false},"author":7,"featured_media":53798,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[46],"tags":[760,757,761,451],"class_list":["post-54030","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-science","tag-biotechnology","tag-bric-en","tag-faculty-of-health-and-medicine","tag-novo-nordisk-en","expression-news_article"],"acf":[],"aioseo_notices":[],"yoast_head":"\n
DKK 100m to new UCPH blood cancer research<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/uniavisen.dk\/en\/100-mio-til-ny-forskning-blodkraeft-paa-ku\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DKK 100m to new UCPH blood cancer research\" \/>\n<meta property=\"og:description\" content=\"It is the latest huge grant from the Novo Nordisk Foundation to UCPH. Researchers are to find new treatments for two types of blood cancer. The development of drugs for these diseases came to a standstill many years ago.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/uniavisen.dk\/en\/100-mio-til-ny-forskning-blodkraeft-paa-ku\/\" \/>\n<meta property=\"og:site_name\" content=\"University Post\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/uniavis\" \/>\n<meta property=\"article:author\" content=\"https:\/\/www.facebook.com\/christoffer.zieler\" \/>\n<meta property=\"article:published_time\" content=\"2017-08-30T07:32:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-08-31T08:33:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/uniavisen.dk\/wp-content\/uploads\/2017\/08\/skaermbillede20170828kl.15.27.42-e1503927099410.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1881\" \/>\n\t<meta property=\"og:image:height\" content=\"1065\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Christoffer Zieler\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Uniavisen\" \/>\n<meta name=\"twitter:site\" content=\"@Uniavisen\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Christoffer Zieler\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/uniavisen.dk\\\/en\\\/100-mio-til-ny-forskning-blodkraeft-paa-ku\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/uniavisen.dk\\\/en\\\/100-mio-til-ny-forskning-blodkraeft-paa-ku\\\/\"},\"author\":{\"name\":\"Christoffer Zieler\",\"@id\":\"https:\\\/\\\/uniavisen.dk\\\/#\\\/schema\\\/person\\\/a96cc389f544930451424dd312b34b8c\"},\"headline\":\"DKK 100m to new UCPH blood cancer research\",\"datePublished\":\"2017-08-30T07:32:08+00:00\",\"dateModified\":\"2017-08-31T08:33:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/uniavisen.dk\\\/en\\\/100-mio-til-ny-forskning-blodkraeft-paa-ku\\\/\"},\"wordCount\":739,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/uniavisen.dk\\\/en\\\/100-mio-til-ny-forskning-blodkraeft-paa-ku\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/uniavisen.dk\\\/wp-content\\\/uploads\\\/2017\\\/08\\\/skaermbillede20170828kl.15.27.42-e1503927099410.png\",\"keywords\":[\"biotechnology\",\"BRIC\",\"Faculty of Health and Medicine\",\"Novo Nordisk\"],\"articleSection\":[\"Science\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/uniavisen.dk\\\/en\\\/100-mio-til-ny-forskning-blodkraeft-paa-ku\\\/\",\"url\":\"https:\\\/\\\/uniavisen.dk\\\/en\\\/100-mio-til-ny-forskning-blodkraeft-paa-ku\\\/\",\"name\":\"DKK 100m to new UCPH blood cancer research\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/uniavisen.dk\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/uniavisen.dk\\\/en\\\/100-mio-til-ny-forskning-blodkraeft-paa-ku\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/uniavisen.dk\\\/en\\\/100-mio-til-ny-forskning-blodkraeft-paa-ku\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/uniavisen.dk\\\/wp-content\\\/uploads\\\/2017\\\/08\\\/skaermbillede20170828kl.15.27.42-e1503927099410.png\",\"datePublished\":\"2017-08-30T07:32:08+00:00\",\"dateModified\":\"2017-08-31T08:33:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/uniavisen.dk\\\/#\\\/schema\\\/person\\\/a96cc389f544930451424dd312b34b8c\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/uniavisen.dk\\\/en\\\/100-mio-til-ny-forskning-blodkraeft-paa-ku\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/uniavisen.dk\\\/en\\\/100-mio-til-ny-forskning-blodkraeft-paa-ku\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/uniavisen.dk\\\/en\\\/100-mio-til-ny-forskning-blodkraeft-paa-ku\\\/#primaryimage\",\"url\":\"https:\\\/\\\/uniavisen.dk\\\/wp-content\\\/uploads\\\/2017\\\/08\\\/skaermbillede20170828kl.15.27.42-e1503927099410.png\",\"contentUrl\":\"https:\\\/\\\/uniavisen.dk\\\/wp-content\\\/uploads\\\/2017\\\/08\\\/skaermbillede20170828kl.15.27.42-e1503927099410.png\",\"width\":1881,\"height\":1065,\"caption\":\"Professor Kristian Helin leder den nye forskningssatsning p\u00e5 KU.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/uniavisen.dk\\\/en\\\/100-mio-til-ny-forskning-blodkraeft-paa-ku\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/uniavisen.dk\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DKK 100m to new UCPH blood cancer research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/uniavisen.dk\\\/#website\",\"url\":\"https:\\\/\\\/uniavisen.dk\\\/\",\"name\":\"University Post\",\"description\":\"Independent of management\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/uniavisen.dk\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/uniavisen.dk\\\/#\\\/schema\\\/person\\\/a96cc389f544930451424dd312b34b8c\",\"name\":\"Christoffer Zieler\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4bf8592c5d42f63ff76abd26557ba3887d83a2e784a2508b81d423cf582346fa?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4bf8592c5d42f63ff76abd26557ba3887d83a2e784a2508b81d423cf582346fa?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4bf8592c5d42f63ff76abd26557ba3887d83a2e784a2508b81d423cf582346fa?s=96&d=identicon&r=g\",\"caption\":\"Christoffer Zieler\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/christoffer.zieler\"],\"url\":\"https:\\\/\\\/uniavisen.dk\\\/en\\\/author\\\/christoffer\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DKK 100m to new UCPH blood cancer research","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/uniavisen.dk\/en\/100-mio-til-ny-forskning-blodkraeft-paa-ku\/","og_locale":"en_US","og_type":"article","og_title":"DKK 100m to new UCPH blood cancer research","og_description":"It is the latest huge grant from the Novo Nordisk Foundation to UCPH. Researchers are to find new treatments for two types of blood cancer. The development of drugs for these diseases came to a standstill many years ago.","og_url":"https:\/\/uniavisen.dk\/en\/100-mio-til-ny-forskning-blodkraeft-paa-ku\/","og_site_name":"University Post","article_publisher":"https:\/\/www.facebook.com\/uniavis","article_author":"https:\/\/www.facebook.com\/christoffer.zieler","article_published_time":"2017-08-30T07:32:08+00:00","article_modified_time":"2017-08-31T08:33:42+00:00","og_image":[{"width":1881,"height":1065,"url":"https:\/\/uniavisen.dk\/wp-content\/uploads\/2017\/08\/skaermbillede20170828kl.15.27.42-e1503927099410.png","type":"image\/png"}],"author":"Christoffer Zieler","twitter_card":"summary_large_image","twitter_creator":"@Uniavisen","twitter_site":"@Uniavisen","twitter_misc":{"Written by":"Christoffer Zieler","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/uniavisen.dk\/en\/100-mio-til-ny-forskning-blodkraeft-paa-ku\/#article","isPartOf":{"@id":"https:\/\/uniavisen.dk\/en\/100-mio-til-ny-forskning-blodkraeft-paa-ku\/"},"author":{"name":"Christoffer Zieler","@id":"https:\/\/uniavisen.dk\/#\/schema\/person\/a96cc389f544930451424dd312b34b8c"},"headline":"DKK 100m to new UCPH blood cancer research","datePublished":"2017-08-30T07:32:08+00:00","dateModified":"2017-08-31T08:33:42+00:00","mainEntityOfPage":{"@id":"https:\/\/uniavisen.dk\/en\/100-mio-til-ny-forskning-blodkraeft-paa-ku\/"},"wordCount":739,"commentCount":0,"image":{"@id":"https:\/\/uniavisen.dk\/en\/100-mio-til-ny-forskning-blodkraeft-paa-ku\/#primaryimage"},"thumbnailUrl":"https:\/\/uniavisen.dk\/wp-content\/uploads\/2017\/08\/skaermbillede20170828kl.15.27.42-e1503927099410.png","keywords":["biotechnology","BRIC","Faculty of Health and Medicine","Novo Nordisk"],"articleSection":["Science"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/uniavisen.dk\/en\/100-mio-til-ny-forskning-blodkraeft-paa-ku\/","url":"https:\/\/uniavisen.dk\/en\/100-mio-til-ny-forskning-blodkraeft-paa-ku\/","name":"DKK 100m to new UCPH blood cancer research","isPartOf":{"@id":"https:\/\/uniavisen.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/uniavisen.dk\/en\/100-mio-til-ny-forskning-blodkraeft-paa-ku\/#primaryimage"},"image":{"@id":"https:\/\/uniavisen.dk\/en\/100-mio-til-ny-forskning-blodkraeft-paa-ku\/#primaryimage"},"thumbnailUrl":"https:\/\/uniavisen.dk\/wp-content\/uploads\/2017\/08\/skaermbillede20170828kl.15.27.42-e1503927099410.png","datePublished":"2017-08-30T07:32:08+00:00","dateModified":"2017-08-31T08:33:42+00:00","author":{"@id":"https:\/\/uniavisen.dk\/#\/schema\/person\/a96cc389f544930451424dd312b34b8c"},"breadcrumb":{"@id":"https:\/\/uniavisen.dk\/en\/100-mio-til-ny-forskning-blodkraeft-paa-ku\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/uniavisen.dk\/en\/100-mio-til-ny-forskning-blodkraeft-paa-ku\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/uniavisen.dk\/en\/100-mio-til-ny-forskning-blodkraeft-paa-ku\/#primaryimage","url":"https:\/\/uniavisen.dk\/wp-content\/uploads\/2017\/08\/skaermbillede20170828kl.15.27.42-e1503927099410.png","contentUrl":"https:\/\/uniavisen.dk\/wp-content\/uploads\/2017\/08\/skaermbillede20170828kl.15.27.42-e1503927099410.png","width":1881,"height":1065,"caption":"Professor Kristian Helin leder den nye forskningssatsning p\u00e5 KU."},{"@type":"BreadcrumbList","@id":"https:\/\/uniavisen.dk\/en\/100-mio-til-ny-forskning-blodkraeft-paa-ku\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/uniavisen.dk\/en\/"},{"@type":"ListItem","position":2,"name":"DKK 100m to new UCPH blood cancer research"}]},{"@type":"WebSite","@id":"https:\/\/uniavisen.dk\/#website","url":"https:\/\/uniavisen.dk\/","name":"University Post","description":"Independent of management","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/uniavisen.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/uniavisen.dk\/#\/schema\/person\/a96cc389f544930451424dd312b34b8c","name":"Christoffer Zieler","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/4bf8592c5d42f63ff76abd26557ba3887d83a2e784a2508b81d423cf582346fa?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4bf8592c5d42f63ff76abd26557ba3887d83a2e784a2508b81d423cf582346fa?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4bf8592c5d42f63ff76abd26557ba3887d83a2e784a2508b81d423cf582346fa?s=96&d=identicon&r=g","caption":"Christoffer Zieler"},"sameAs":["https:\/\/www.facebook.com\/christoffer.zieler"],"url":"https:\/\/uniavisen.dk\/en\/author\/christoffer\/"}]}},"advancedCustomFields":{"layout_group":[{"acf_fc_layout":"Headline","use_post_title":true,"headline":"","style":"default","highlighted_words":"","text_size":"small"},{"acf_fc_layout":"Image","image":{"ID":53798,"id":53798,"title":"Sk\u00e6rmbillede 2017-08-28 kl. 15.27.42","filename":"skaermbillede20170828kl.15.27.42-e1503927099410.png","filesize":1111347,"url":"https:\/\/uniavisen.dk\/wp-content\/uploads\/2017\/08\/skaermbillede20170828kl.15.27.42-e1503927099410.png","link":"https:\/\/uniavisen.dk\/en\/100-mio-til-ny-forskning-blodkraeft-paa-ku\/skaermbillede-2017-08-28-kl-15-27-42\/","alt":"","author":"7","description":"Professor Kristian Helin i video fra KU's pressemeddelelse om bevillingen p\u00e5 100 mio i august 2017 fra Novo Nordisk Fonden.","caption":"Professor Kristian Helin leder den nye forskningssatsning p\u00e5 KU.","name":"skaermbillede-2017-08-28-kl-15-27-42","status":"inherit","uploaded_to":53779,"date":"2017-08-28 13:28:00","modified":"2017-08-28 13:31:46","menu_order":0,"mime_type":"image\/png","type":"image","subtype":"png","icon":"https:\/\/uniavisen.dk\/wp-includes\/images\/media\/default.png","width":1881,"height":1065,"sizes":{"thumbnail":"https:\/\/uniavisen.dk\/wp-content\/uploads\/2017\/08\/skaermbillede20170828kl.15.27.42-e1503927099410-150x150.png","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/uniavisen.dk\/wp-content\/uploads\/2017\/08\/skaermbillede20170828kl.15.27.42-e1503927099410-480x272.png","medium-width":480,"medium-height":272,"medium_large":"https:\/\/uniavisen.dk\/wp-content\/uploads\/2017\/08\/skaermbillede20170828kl.15.27.42-e1503927099410-768x435.png","medium_large-width":768,"medium_large-height":435,"large":"https:\/\/uniavisen.dk\/wp-content\/uploads\/2017\/08\/skaermbillede20170828kl.15.27.42-e1503927099410-1280x725.png","large-width":1280,"large-height":725,"1536x1536":"https:\/\/uniavisen.dk\/wp-content\/uploads\/2017\/08\/skaermbillede20170828kl.15.27.42-e1503927099410.png","1536x1536-width":1536,"1536x1536-height":870,"2048x2048":"https:\/\/uniavisen.dk\/wp-content\/uploads\/2017\/08\/skaermbillede20170828kl.15.27.42-e1503927099410.png","2048x2048-width":1881,"2048x2048-height":1065,"featured-soft":"https:\/\/uniavisen.dk\/wp-content\/uploads\/2017\/08\/skaermbillede20170828kl.15.27.42-e1503927099410-290x164.png","featured-soft-width":290,"featured-soft-height":164,"featured-hard":"https:\/\/uniavisen.dk\/wp-content\/uploads\/2017\/08\/skaermbillede20170828kl.15.27.42-e1503927099410-290x180.png","featured-hard-width":290,"featured-hard-height":180,"narrow":"https:\/\/uniavisen.dk\/wp-content\/uploads\/2017\/08\/skaermbillede20170828kl.15.27.42-e1503927099410-700x396.png","narrow-width":700,"narrow-height":396,"extended":"https:\/\/uniavisen.dk\/wp-content\/uploads\/2017\/08\/skaermbillede20170828kl.15.27.42-e1503927099410-990x561.png","extended-width":990,"extended-height":561}},"style":"narrow","text_placement":"metadata-below","image_link_url":"","image_link_title":"","caption_prefix":"","enable_alternative_caption":true,"alternative_caption":"Professor Kristian Helin talks about how the grant is to be used in a video clip on the University of Copenhagen's website."},{"acf_fc_layout":"Standfirst","subject":"","text":"It is the latest huge grant from the Novo Nordisk Foundation to UCPH. Researchers are to find new treatments for two types of blood cancer. The development of drugs for these diseases came to a standstill many years ago.","use_post_excerpt":false},{"acf_fc_layout":"Byline","is_author":true,"contributors":false},{"acf_fc_layout":"Content","content":"<p>“As a scientist you find out that at some point it is fun to publish, but it is even better to influence how patients are treated. That’s my angle,” says Kristian Helin.<\/p>\n<p>He is a professor, the director of the biomedical research center BRIC at the University of Copenhagen (UCPH), and now the head of a brand new research programme at UCPH which has been launched with a grant of DKK 100 million from the Novo Nordisk Foundation.<\/p>\n<p>The money is to go to the development of new blood cancer treatments.<\/p>\n<p>“We want to develop new therapies and make better use of existing drugs,” says Kristian Helin. “We take the research results we have into the clinic – and the results we get in the clinic into research.”<\/p>\n<p>The research is to take place in the stem cell centre <secret text=\"Its full name is Novo Nordisk Foundation Center for Stem Cell Biology\">DanStem<\/secret>, which has been built up with two large previous Novo grants.<\/p>\n<p>The Novo Nordisk Foundation has donated a total of DKK 685 million to the stem cell center since 2010. Cancer stem cells are interesting because they are often resistant to treatment and give rise to new tumors.<\/p>\n<p>“Our underlying theme is to find funds to specifically kill those cancer stem cells,” says Kristian Helin.<\/p>\n<h3>Research programme can be extended nationwide<\/h3>\n<p>“The grant has allowed us to employ two new research managers at the stem cell centre and at BRIC, so the money does not only go to existing research groups,” says Kristian Helin.<\/p>\n<p>“We have already recruited a professor from Finland and we have set up a position as head of research. We get new people to the university, and I think that’s important.”<\/p>\n<p>The research project also involves clinicians from Copenhagen\u2019s hospital Rigshospitalet, and a <em>clinical academic group<\/em> with people from the hospitals in Herlev and Roskilde. Kristian Helin is hoping to receive support from the Danish Cancer Society’s national research fund to expand the research to all the country’s <secret text=\"hematology is the study of diseases of the blood.\">hematology<\/secret> hospital departments.<\/p>\n<p>“In recent years, institutional boundaries have been broken down slightly when we work with major research projects. We know more and more, and we need to try to convert this knowledge into direct treatment,” says Kristian Helin.<\/p>\n<p>One task is to collect and characterize patient material, i.e. cancer cells. If you have cells, you can then test the effect of new drugs on them, and you can use them for <a href=\"https:\/\/en.wikipedia.org\/wiki\/Genetic_screen\">genetic screens<\/a> to find new targets for medical treatment.<\/p>\n<p>In preclinical trials, researchers will often implant human cancer cells into mice and test new treatments on them.<\/p>\n<h3>Need for new treatment<\/h3>\n<p>Two types of cancer have the researchers’ attention specifically, namely <a href=\"https:\/\/www.cancer.dk\/akut-leukaemi-all-aml\/statistik-akut-leukaemi\/statistik-akut-myeloid-leukaemi\/\">AML<\/a> (Acute Myeloid Leukemia) and <a href=\"https:\/\/www.cancer.dk\/myelodysplastisk-syndrom-mds\/\">MDS <\/a>(Myelodysplastic Syndrome).<\/p>\n<p>According to the Danish Cancer Society, approximately 100 men and 80 women in Denmark get AML every year, and the disease has a high mortality rate. MDS affects around 230 people a year in Denmark, and many get the disease as a chronic condition, that is, they live with MDS and get treatment for it.<\/p>\n<p>If the researchers succeed in developing a new treatment for the two diseases, it will be a breakthrough.<\/p>\n<p>“Clearly, there is a need for better treatment,” says Kristian Helin. “In the case of AML, there has been virtually no new treatment options over the past 40 years. Generally, about 30 per cent of patients survive over a five-year period, and this is, of course, not good enough. With MDS you can survive for much longer, but the disease often develops into a secondary AML. The diseases have many common features. ”<\/p>\n<p>Kristian Helin says that the researchers will try to limit themselves and keep their focus.<\/p>\n<p>“The hope is that we can make a difference by focusing. And that we can later gain more resources and transfer the way we work to other types of cancer.”<\/p>\n<h3>Novo Nordisk Foundation has donated billions to UCPH<\/h3>\n<p>UCPH research has also previously been significant for Novo Nordisk. In 2009 it was able to put the lucrative drug <a href=\"https:\/\/en.wikipedia.org\/wiki\/Liraglutide\">Liraglutide <\/a>on the market. It was based on University of Copenhagen research.<\/p>\n<p>There is also an extensive exchange of employees between UCPH and Novo Nordisk.<\/p>\n<p>In total, the Novo Nordisk Foundation has <a href=\"https:\/\/uniavisen.dk\/en\/friends-with-benefits-ucph-and-novo-go-to-the-next-base\/\">spent around DKK 2.5 billion<\/a> on research centres at the University of Copenhagen since 2007.<\/p>\n"},{"acf_fc_layout":"ArticleEnd"},{"acf_fc_layout":"Banner","img":false,"url":""},{"acf_fc_layout":"OtherStories","headline":"","hand_picked_posts":true,"references":[{"reference":{"ID":47451,"post_author":"7","post_date":"2017-04-20 10:45:55","post_date_gmt":"2017-04-20 08:45:55","post_content":"Follow the money sounds like good advice. And Novo Nordisk has apparently followed it when one of their executives - Executive Vice President for Research and Development [secretimage face=\"Mads Krogsgaard Thomsen\" imageid=\"46430\"] - recently got the job as new chairman of the University Board.\r\n\r\nThe money comes from the company itself. It comes from the Novo Nordisk Foundation, which (via Novo A\/S) owns a controlling majority shareholding in Novo Nordisk and its sister company Novozymes. Novo Nordisk is the largest pharmaceutical company in Denmark and the country's most valuable company.\r\n\r\nJust within the last 10 years, the Novo Nordisk Foundation has spent almost DKK 2.5bn on setting up [secrettext face=\"research centers\" text=\"Novo Nordisk Foundation has also set up a DKK 1.3 billion center at the Technical University of Denmark (DTU), and here it is Novozymes' former head of research that is chairman of the board\"] at the University of Copenhagen\u2019s Faculty of Health and Medical Sciences. At the head of the Novo Nordisk Foundation is its director Birgitte Nauntofte, who is a former associate dean of the Faculty.\r\n<h2>Two versions<\/h2>\r\nThe close connection between the university and the company is striking, but there are at least two different interpretations of what it means for the country's largest university.\r\n\r\nIn <em>one<\/em> version, Novo Nordisk, through its economic strength and experience as a research-based company, can guarantee the university\u2019s autonomy and development. It can shield the university from politicians' short-termist solutions and their desire for detailed regulation.\r\n\r\nIn the <em>second<\/em> version, it is in fact a merger between UCPH and the Novo-family: the privatization of research in Denmark, as the former member of the UCPH board Leif S\u00f8ndergaard called it. He's not the only one who sees danger signs.\r\n\r\n\"It always means trouble when you go to bed with an elephant,\" says Allan Randrup Thomsen, professor, doctor and member of the central staff co-operation committee at UCPH.\r\n\r\nRandrup Thomsen says that his attitude towards the Novo Nordisk Foundation is ambivalent, partly because he is \"reluctant to bite the hand that feeds me,\" partly because Novo \u2013 not least through the statements of Mads Krogsgaard Thomsen \u2013 is a large and ardent supporter of research in Denmark.\r\n\r\n\"That said, Novo's dominance at UCPH is also a problem. The Novo Nordisk Foundation centres are very dominant and, when it comes to the competition for funding, they are hard to compete with,\" he says.\r\n\r\n\"Even our own faculty interests seem, to some extent, to follow Novo's priorities. And with such a dominant partner this is not without problems. I think that our situation to a certain extent is comparable to Finland's relationship with Russia. Finland is an independent country, but it always needs to take Russia into account.\"\r\n<div class=\"factbox\">\r\n<p class=\"factbox-header feature-color\">Long engagement<\/p>\r\nThe relationship between the University of Copenhagen and the country's [secrettext face=\"largest pharmaceutical company\" text=\"and the largest company of all in terms of market value\"] is an old one. In fact, the relationship began at UCPH when professor and Nobel laureate August Krogh (1874-1949) in 1923 became one of the three founders of Nordisk Insulinlaboratorium, which eventually became part of Novo Nordisk.\r\n\r\n<\/div>\r\nHeine Andersen, professor emeritus of sociology and an active debater in the area of research policy, notes the fact that Novo Nordisk is an exceptional partner with the universities \u2013 simply by virtue of its size.\r\n\r\n\"There is loads of collaboration with industries, agriculture and business, but rarely with such strong partners,\" says Heine Andersen.\r\n\r\n\"It is clear that this has given rise to speculation among many people \u2013 but it is rare that you encounter it in the form of concerns these days. In most places, politicians and university leaders applaud it, and many researchers are, of course, happy for the money. This is really disturbing.\u201d\r\n\r\n \r\n\r\n \r\n\r\n \n<!-- end of module 1 -->\nThomas Vils Pedersen, associate professor and representative for the academic staff at UCPH, says that the main problem with large external funders is that they can get the university to opt out of strategic initiatives that it would have liked.\r\n\r\n\"It applies to all the places where UCPH gets research grants that do not cover all the costs of the research. This means that the university effectively co-finances everything, and this is fine if this is inside a field that you already want to focus on.\"\r\n\r\n\"The individual managements of faculties or departments need to better assess whether they should co-finance the privately funded projects and thereby at the same time opt out of other projects. Otherwise, this is an attack on academic freedom.\"\r\n\r\n\"There are good examples,\" says Thomas Vils Pedersen, \"but you have to be aware of this choice.\"\r\n\r\nVils Pedersen does not mention any examples of Novo money doing any harm to the freedom of research, but one possible example would be <a href=\"https:\/\/www.information.dk\/indland\/2010\/05\/novo-bestilte-center-paa-koebenhavns-universitet\">the story <\/a>that the Danish newspaper Information published in 2010 on the Novo Nordisk Foundation\u2019s DKK 885 million metabolic research center donation. The newspaper revealed then that the metabolism center was established because the Novo Nordisk Foundation thought it would be a good idea \u2013 not because the UCPH had any plans for a center.\r\n\r\nThe Foundation\u2019s director Birgitte Nauntofte had, according to the newspaper Information, contacted her old boss at UCPH, the dean Ulla Wewer, and suggested that UCPH apply for funding for a center.\r\n\r\nIt was clear from the newspaper Information\u2019s coverage that the Novo Nordisk Foundation retained some control over the use of their money at UCPH. Nauntofte and Wewer made up the committee, \"that should approve the Center's overall strategy, management and development, and approve the budget.\" If Wewer was to leave the committee, the Foundation had to approve her successor.\r\n\r\nIt was in this context that the former staff representative Leif S\u00f8ndergaard (who has also been a member of the UCPH Board) talked of the <em>privatization<\/em> of public research in Denmark.\r\n<h2>Highway of PhDs<\/h2>\r\nAccording to the sceptics, it can also be a problem that the large research centers represent a kind of highway for young researchers that automatically directs them in the scientific direction that the funders want.\r\n<div class=\"factbox\">\r\n<p class=\"factbox-header feature-color\">Exchange of personnel between UCPH and Novo<\/p>\r\nNovo Nordisk and the foundation are not only associated with UCPH through donations. It also takes place through the <strong>exchange of staff<\/strong>. A new report from the The Danish Council for Research and Innovation Policy states that Novo Nordisk hires 20 per cent of its employees from the academic world (in addition to the 18 per cent they hire directly). But more importantly: <strong>9 per cent of Novo\u2019s resignations are because the person got a job in the university world.<\/strong>\r\n\r\n<\/div>\r\n\u201cYou should ensure that a certain amount PhD scholarships are free grants, so that the best minds can get the chance to develop their own ideas,\" says staff representative Thomas Vils Pedersen.\r\n\r\nThomas Vils Pedersen also says that he has no reason for believing that the Board will interfere in specific research programmes in the faculties. But he says that it is of course important that members do not have a conflict of interest \u2013 in particular the chairman.\r\n\r\n\"It is a point that should be noticed,\" he says. \"But specifically Mads Krogsgaard Thomsen has sent some good signals as an advocate for independent research.\"\r\n\r\nKrogsgaard Thomsen has in several featured comments in recent years argued that Denmark should invest more in research \u2013 especially in the <a href=\"https:\/\/www.b.dk\/kronikker\/life-science-skal-have-en-national-strategi\">life sciences<\/a> \u2013 and that it should raise the quality of its PhD programmes and recruit more internationally.\r\n<h2>Disqualification rules should make the chairman cautious<\/h2>\r\n\"Whether you can be honestly impartial is something for a psychological evaluation,\" says Johan Tufte-Kristensen, who is putting his final touches on a PhD thesis on incapacity standards.\r\n\r\n\"Some people would say that you can be dispassionate. Others will not. But there is hardly any doubt that an executive vice president at Novo Nordisk will normally be able to manage university funds.\"\r\n\r\n\"What you could consider is whether the connection between the Novo Nordisk Foundation's investments and the chairman\u2019s job can in certain situations make the outside world frown upon it. It is partly to prevent the outside world from looking askance at this, that we have disqualification rules in a number of areas.\u201d\r\n\r\n\"There is nothing in law from preventing the same person being the chairman of UCPH and executive vice director of Novo Nordisk, so long as he does not participate in the consideration of issues related to Novo Nordisk.\"\r\n\r\n\"In corporate legal terms there is a firewall between the Foundation and the company, but the talk of a firewall does not hold in the sense of disqualification. The two actors are of course inextricably linked due to the Foundation's ownership of Novo Nordisk. You can ask yourself whether Novo Nordisk does not also have an interest in the Foundation's operations.\"\r\n\r\n\"If the chairman deals with specific questions related to the Novo Nordisk Foundation projects, it will be the cause of concern in the outside world. If the alignment of interests between the chairman and the foundation is big enough, it may even be contrary to the disqualification rules in the Danish Law on Public Administration and the Board\u2019s own rules of procedure. But if he withdraws from the examination of specific questions, there should be no problem.\"\r\n\r\n \n<!-- end of module 2 -->\nThe Novo and UCPH marriage is a part of a general development where universities and the business sector, with the blessing of politicians and rectors, approach each other. The UCPH management is deeply committed to making the science campus areas the central neighborhoods in a Copenhagen science city, where the idea is that many companies can move in and absorb graduates and PhDs from the University.\r\n\r\n\"There is alot going on. They want to mix up the private and public sector. Those from outside the university are expected to contribute with something different or new,\" says Carsten Greve, a professor of public governance and management at CBS.\r\n\r\nIn this narrative, it is natural that the University and Novo join forces. Maybe Krogsgaard Thomsens chairmanship can even be seen as a strengthening of the university\u2019s autonomy. The scientific community can, in an alliance with the captains of industry, become strong enough to take on the civil servants at the ministry when they, and their political bosses, want to regulate academia.\r\n<h2>Countercoup<\/h2>\r\nIn fact, the appointment of Mads Krogsgaard Thomsen happened in a way where UCPH stood up to government in Christiansborg.\r\n\r\nThe UCPH Board's decision to choose Mads Krogsgaard Thomsen as chairman was taken in urgency in March after the government announced that it would henceforth take over control of who should lead the country's universities (in particular at the expense of the universities' own staff and students).\r\n\r\nThe government bill is to be adopted as law on 1st July, and UCPH decided \u2013 in a kind of <a href=\"https:\/\/uniavisen.dk\/en\/the-race-is-on-ucph-needs-to-appoint-new-board-members-before-law-is-changed\/\">counter-coup against the government <\/a>\u2013 to push forward a change of chairman, which otherwise was scheduled to take place this autumn, so that the Minister of Higher Education and Research did not, this time, have a say in who sits at the end of the table in the University's boardroom.\r\n\r\nKrogsgaard Thomsen\u2019s rapid entry does not mean that he does not know UCPH well. The Novo executive vice director has already served as a \u00a0[secrettext face=\"non-executive board member\" text=\"Along with other people coming from companies or organizations that donate\u00a0large amounts of money to UCPH, like Peter G\u00e6melke, the former president of the Agriculture Council, and Jakob Thomasen, director of Maersk Oil.\"] at UCPH for four years.\r\n<div class=\"factbox\">\r\n<p class=\"factbox-header feature-color\">The centers<\/p>\r\nThe Novo Nordisk Foundation that owns Novo A\/S (and therefore both Novo Nordisk and Novozymes), has in the last 10 years donated DKK 3.7 billion to set up four research centers and a national biobank. Three of the centers are located at UCPH.\r\n\r\n2013: DKK 100m as a contribution to the establishment of a new Natural History Museum at UCPH.\r\n\r\n2010-14: DKK 15m to a Center for Global Health.\r\n\r\n2010 + 2015: DKK 585m to basic research unit in stem cell biology\r\n\r\n2007-14: DKK 780m for protein research center\r\n\r\n2010: DKK 885m or metabolism research center\r\n\r\nTotal: DKK 2,365m\r\n\r\nIn addition, awards such as the Novo Nordisk Prize (DKK 3m annually) and grants for research projects on application.\r\n\r\n<\/div>\r\n<h2>Chairmen generally end up being university people<\/h2>\r\nProfessor emeritus J\u00f8rgen Gr\u00f8nneg\u00e5rd Christensen of the University of Aarhus is the grand old man of research in management and bureaucracy in Denmark. He is not frightened by the election of Mads Krogsgaard Thomsen.\r\n\r\n\"I see no major problems in it off hand,\" he writes in an email.\r\n\r\n\"Of course there will be cases where Krogsgaard may have a conflict of interest. But, for the first, as university boards work, these will be few and far between, and for the second, there are rules for how to proceed in this case.\"\r\n\r\nHe too takes note of the new chairman\u2019s merits:\r\n\r\n\"With Krogsgaard, UCPH gets a chairman of the board that has the right professional attitude to running higher education and research. And he can do nothing on his own,\u201d writes J\u00f8rgen Gr\u00f8nneg\u00e5rd Christensen.\r\n\r\nThe government wants, as mentioned above, to appoint board chairmen at universities and in this way gain more control over the sector.\r\n\r\nBut in an opinion piece in the Weekendavisen newspaper (10th March 2017) Gr\u00f8nneg\u00e5rd Christensen questions whether this kind of detailed management will serve the government's purpose at all. It is in no way certain that board executives will stand to attention for the minister just because the government had a hand in appointing them:\r\n\r\n'[With] everything we know about a public organization, it is an illusion that the new ministerially appointed board chairmen will orient themselves towards the Minister rather than the university,\" writes J\u00f8rgen Gr\u00f8nneg\u00e5rd Christensen in Weekendavisen.\r\n<h2>Board members represent the university, when they are asked<\/h2>\r\nIf Mads Krogsgaard Thomsen is therefore primarily the university\u2019s man in the role of chairman \u2013 and not the envoy of Novo \u2013 this corresponds very well with how board members at Danish universities perceive their own role.\r\n\r\nThis is according to Niels Ejersbo, senior researcher at KORA (the Danish Institute for Local and Regional Government Research), who together with Professor Carsten Greve, CBS, has done research on how the members of the university\u2019s boards perceive their tasks.\r\n\r\n\"The literature describes several roles that a board can have. The members can devote themselves to supervising the daily management in accordance with a strategy, or they can see themselves more in a supportive role, assisting management with its work. But in addition, the board members can also see themselves as representatives of interests outside the university, as stakeholders. When we ask how they see themselves, they answer yes to the first two things, but they do not see themselves as stakeholder representatives.\"\r\n<h2>Cash flows<\/h2>\r\nEjersbo and Greve have also found that there is a strong consensus within the boards, and there is no sign of a stand-off between the members coming from the university and the majority that is taken in from outside.\r\n\r\n\"There was no evidence of a line of conflict between the two parties,\" says Niels Ejersbo.\r\n\r\nThis also corresponds well with how the Board appears in public. There is rarely dissent in their decisions, and even the toughest student politician tends to calm down and play by the rules of consensus when he or she is first elected to the University's governing body. If there are quarrels, they are typically kept confidential.\r\n\r\nIt will therefore, also in the coming years, be interesting to follow the cash flows. Not only those from the Novo Nordisk Foundation, but also UCPH\u2019s own funds. Will they also overwhelmingly flow in the direction of [secrettext face=\"life science\" text=\"Bonus Info: Novo Nordisk CEO from 2000-2017 Lars Rebien S\u00f8rensen (educated at agricultural college KVL, that has now been merged into UCPH), has this year been made a new honorary alumnus at the University of Copenhagen.\"]?\r\n\r\n<em>It has not been possible before the deadline to get an interview with Mads Krogsgaard Thomsen.<\/em>\n<!-- end of module 3 -->\n","post_title":"Friends with benefits: UCPH and Novo go to the next base","post_excerpt":"The Novo Nordisk Foundation has put billions into the University of Copenhagen. Now one of the top people from the foundation\u2019s company Novo Nordisk has been made the new chairman of the University\u2019s board. What is the significance of the marriage between the university and the pharmaceutical industry?","post_status":"publish","comment_status":"open","ping_status":"open","post_password":"","post_name":"friends-with-benefits-ucph-and-novo-go-to-the-next-base","to_ping":"","pinged":"","post_modified":"2017-04-20 10:46:54","post_modified_gmt":"2017-04-20 08:46:54","post_content_filtered":"","post_parent":0,"guid":"https:\/\/uniavisen.dk\/friends-with-benefits-ku-novo-tager-naeste-skridt\/","menu_order":0,"post_type":"post","post_mime_type":"","comment_count":"0","filter":"raw"}},{"reference":{"ID":4272,"post_author":"12","post_date":"2015-12-03 11:11:02","post_date_gmt":"0000-00-00 00:00:00","post_content":"\nP\u00e5 DanStem forsker professor og centerdirekt\u00f8r Henrik Sembs teams i, hvilken betydning stamceller har i b\u00e5de den raske og syge krop. Stamcellerne er en vital del af organismen, men vores viden om kroppens byggesten er langtfra komplet. \r\n\r\nHenik Semb gl\u00e6der sig derfor over, at donationen p\u00e5 235 millioner kroner g\u00f8r det muligt at forts\u00e6tte forskningen i stamceller. S\u00e6rligt deres betydning for is\u00e6r diabetes- og cancerpatienter.\r\n\r\n\u00bbVed at studere stamceller l\u00e6rer vi, hvordan kroppen udvikler sig under normale omst\u00e6ndigheder. Men ogs\u00e5 hvordan stamceller p\u00e5virker forskellige sygdomsprocesser. Det betyder i sidste ende, at vi kan udvikle nye redskaber til at behandle sygdomme. Enten i form af medicin eller som stamceller, der inds\u00e6ttes i kroppen. Det kan fx v\u00e6re insulinproducerende stamceller, der erstatter betacellerne, som diabetespatienter mangler,\u00ab siger Henrik Semb til Uniavisen. \r\n\r\nId\u00e9en bag DanStem er at opn\u00e5 forskningsresultater i verdensklasse. Derfor er det if\u00f8lge centerdirekt\u00f8ren afg\u00f8rende, at centeret holder fokus p\u00e5 enkelte forskningsomr\u00e5der. Derfor er det prim\u00e6rt stamcellers betydning for diabetes og cancer, som har forskernes interesse. \r\n\r\n\u00bbVores hypotese om cancer er, at canceren opst\u00e5r i en stamcelle. Derfor oplever man ogs\u00e5, at nye medicinske pr\u00e6parater ikke sl\u00e5r canceren ihjel, men blot for stund sl\u00e5r den ned. Men den kommer igen, fordi selve roden til canceren skal findes i stamcellerne. Det er s\u00e6rligt cancertyper i blodet og brystv\u00e6vet, hvor det g\u00f8r sig g\u00e6ldende.\u00ab \r\n\r\n<div class=\"dme-image dme-image-center dme-image-preset-0\"><img src=\"\/old_files\/unknown-1.jpeg\" alt=\"\" title=\"\"><\/div>\n<em>Det hvide er insulin i betaceller, som forskerne har skabt af menneskelige embryonale stamceller. Billedet er taget af Jacqueline Ameri.<\/em>\r\n\r\n<h2>Donation uden forbehold<\/h2>\r\nDanStem og Novo Nordisk Fonden har haft t\u00e6t konktakt siden centerets f\u00f8dsel. Den f\u00f8rste Novo-donation kom for fire \u00e5r siden, da Henrik Semb samtidig blev udpeget til at opbygge og lede centeret. Alligevel forsikrer centerdirekt\u00f8ren, at donationen ikke dikterer centerets forskning.\r\n\r\n\u00bbDonationen bliver givet uden forbehold. Det er ikke en investering fra Novo Nordisk Fonden, men vi h\u00e5ber naturligvis, at vores forskning kan producere resultater, som senere kan v\u00e6re til gavn for samfundet. Set som en udefrakommende er det en unik ting, at man i Danmark har en privat akt\u00f8r, som donerer s\u00e5 meget til grundforskningen.\u00ab \r\n\r\nNovo Nordisk Fonden har i de senere \u00e5r investeret omkring 3,5 milliarder kroner i forskningscentre ved danske universiteter. KU tegner sig for en v\u00e6sentlig del. I 2007 donerede fonden 600 millioner til et proteinforskningscenter, og i 2010 betalte fonden 885 millioner kroner til et center for metabolismeforskning, begge p\u00e5 KU. I 2010 gav Novo Nordisk Fonden desuden 350 millioner kroner til KU's stamcelleforskning - en bevilling, der alts\u00e5 nu f\u00f8lges op med en lille kvart milliard.\r\n\r\nPengene til DanStem skal blandt andet bruges til at tiltr\u00e6kke nye forskningstalenter og forskningsgruppeledere. Centeret er finansieret i ti \u00e5r, men Henrik Semb og hans kollegaer har mulighed for at f\u00e5 centerets finansiering forl\u00e6nget, hvis resultaterne er gode nok. Derfor handler det ogs\u00e5 om at planl\u00e6gge fremtiden for centeret. \r\n\r\n\u00bbSom forskningscenter er vi optaget af at svare p\u00e5 de store og sv\u00e6re sp\u00f8rgsm\u00e5l. Det g\u00f8r man ikke i l\u00f8bet af et par \u00e5r. Det tager noget l\u00e6ngere tid. Og for at v\u00e6re et elite-forskningscenter er det afg\u00f8rende hele tiden at bruge de nyeste teknikker og teknologier. Derfor skal donationen ogs\u00e5 bruges til at udbygge vores teknologiske v\u00e6rkt\u00f8jskasse,\u00ab siger han.\r\n\r\n<h2>Konkrete resultater<\/h2>\r\nN\u00e5r de 235 millioner er brugt, og de ti \u00e5r er g\u00e5et, forventer Henrik Semb, at der ligger konkrete muligheder for b\u00e5de at bruge resultaterne til udviklingen af nye medikamenter og brugen af stamceller i behandlinger. \r\n\r\n\u00bbGrundforskningen er altafg\u00f8rende. Vi er n\u00f8dt til at have steder som DanStem, hvor forskningen er drevet af nysgerrighed,\u00ab p\u00e5peger Henrik Semb. \r\n\r\nHan siger samtidig, at i en verden, hvor der bliver mindre og mindre plads til netop grundforskning, er det afg\u00f8rende, at centeret viser resultater.\r\n\r\n\u00bbN\u00e5r man arbejder med grundforskning, vil der opst\u00e5 muligheder for at g\u00f8re resultaterne brugbare i andre sammenh\u00e6nge. Derfor k\u00f8rer vi ogs\u00e5 to spor p\u00e5 centeret. Det ene fokuserer p\u00e5 grundforskning, mens det andet fokuserer p\u00e5 at g\u00f8re forskningen anvendelig.\u00ab \r\n\r\nHenrik Semb ser frem til de kommende \u00e5r. \r\n\r\n\u00bbMed denne donation er vi i stand til aggressivt at forf\u00f8lge vores m\u00e5l. Det er is\u00e6r positivt for de unge forskere, for de kan se, at centeret har en fremtid. Men ogs\u00e5 personligt er jeg glad for, donationen viser, at vores forskning og resultater er p\u00e5 vej i den rigtige retning.\u00ab\r\n\r\nuni-avis@adm.ku.dk","post_title":"Kvart milliard fra Novo-fond booster stamcelleforskning p\u00e5 KU","post_excerpt":"PENGE - K\u00e6mpebevillingen giver optimisme p\u00e5 forskningscenteret DanStem p\u00e5 SUND. Pengene skaber gode rammer for reel grundforskning, siger centerdirekt\u00f8r Henrik Semb. ","post_status":"publish","comment_status":"open","ping_status":"open","post_password":"","post_name":"kvart-milliard-fra-novo-fond-booster-stamcelleforskning-paa-ku","to_ping":"","pinged":"","post_modified":"2017-01-20 21:27:14","post_modified_gmt":"2017-01-20 21:27:14","post_content_filtered":"","post_parent":0,"guid":"https:\/\/uniavisen.dk\/?p=4272\/","menu_order":0,"post_type":"post","post_mime_type":"","comment_count":"0","filter":"raw"}}],"category":false,"theme":false,"number_of_posts":"4","style":"default"}],"expression":{"term_id":15,"name":"News Article","slug":"news_article","term_group":0,"term_taxonomy_id":15,"taxonomy":"expression","description":"","parent":0,"count":11491,"filter":"raw"},"enable_comments":true,"align_content":"alignleft","feature_color":""},"taxonomyData":{"category":[{"term_id":46,"name":"Science","slug":"science","term_group":0,"term_taxonomy_id":46,"taxonomy":"category","description":"","parent":0,"count":831,"filter":"raw"}],"post_tag":[{"term_id":760,"name":"biotechnology","slug":"biotechnology","term_group":0,"term_taxonomy_id":760,"taxonomy":"post_tag","description":"","parent":0,"count":1,"filter":"raw"},{"term_id":757,"name":"BRIC","slug":"bric-en","term_group":0,"term_taxonomy_id":757,"taxonomy":"post_tag","description":"","parent":0,"count":2,"filter":"raw"},{"term_id":761,"name":"Faculty of Health and Medicine","slug":"faculty-of-health-and-medicine","term_group":0,"term_taxonomy_id":761,"taxonomy":"post_tag","description":"","parent":0,"count":9,"filter":"raw"},{"term_id":451,"name":"Novo Nordisk","slug":"novo-nordisk-en","term_group":0,"term_taxonomy_id":451,"taxonomy":"post_tag","description":"","parent":0,"count":4,"filter":"raw"}],"post_format":[],"expression":[{"term_id":15,"name":"News Article","slug":"news_article","term_group":0,"term_taxonomy_id":15,"taxonomy":"expression","description":"","parent":0,"count":11491,"filter":"raw"}],"translation_priority":[]},"featured_media_url":"https:\/\/uniavisen.dk\/wp-content\/uploads\/2017\/08\/skaermbillede20170828kl.15.27.42-e1503927099410-1280x725.png","_links":{"self":[{"href":"https:\/\/uniavisen.dk\/en\/wp-json\/wp\/v2\/posts\/54030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/uniavisen.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/uniavisen.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/uniavisen.dk\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/uniavisen.dk\/en\/wp-json\/wp\/v2\/comments?post=54030"}],"version-history":[{"count":5,"href":"https:\/\/uniavisen.dk\/en\/wp-json\/wp\/v2\/posts\/54030\/revisions"}],"predecessor-version":[{"id":54049,"href":"https:\/\/uniavisen.dk\/en\/wp-json\/wp\/v2\/posts\/54030\/revisions\/54049"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/uniavisen.dk\/en\/wp-json\/wp\/v2\/media\/53798"}],"wp:attachment":[{"href":"https:\/\/uniavisen.dk\/en\/wp-json\/wp\/v2\/media?parent=54030"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/uniavisen.dk\/en\/wp-json\/wp\/v2\/categories?post=54030"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/uniavisen.dk\/en\/wp-json\/wp\/v2\/tags?post=54030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}